Cellectar Biosciences, Inc. (CLRB: OTCQX U.S.) | Cellectar

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Cellectar Biosciences, Inc. (CLRB: OTCQX U.S.) | Cellectar Biosciences Announces Presentations at 2014 American Society of Clinical Oncology (ASCO) Annual Meeting

MADISON, Wis., May 30, 2014 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (OTCQX:CLRB), announced that presentations highlighting the company's cancer and cancer stem cell-targeting delivery and retention platform of optimized phospholipid ether analogs (PLEs) and its radiotherapeutic agent, I-131-CLR1404, will be presented at the 50 th Annual Meeting of the American Society of Clinical Oncology (ASCO), which is being held from May 30 through June 3, 2014 in Chicago.

Key clinical results to be presented during the meeting include updated data from Cellectar's Phase Ib dose escalation study of I-131-CLR1404 in patients with advanced solid tumors. Additionally, an oral presentation by Dr. Perry Pickhardt will detail the company's core "diapeutic" platform that may allow for combined oncologic imaging and treatment in humans using 124 I-CLR1404 and 131 I-CLR1404, respectively, potentially removing the current disconnect between cancer imaging and therapy.

"This year over 5,500 abstracts were submitted and reviewed by ASCO leadership and its Scientific Program Committee and we are honored that data from our programs will be presented at this year's annual meeting," commented Dr. Jamey Weichert, Cellectar's chief scientific officer and technology founder. "We believe our imaging and therapeutic agents have the potential to create truly personalized cancer care by affording clinicians the potential opportunity to selectively identify malignant tumors, demonstrate and quantify tumor specific uptake to guide subsequent therapy, and monitor treatment progress. We look forward to sharing data that support this 'diapeutic' premise and demonstrates the potential for Cellectar's targeted delivery platform to combine diagnosis and treatment using the same core technology."

Presentations at ASCO 2014 include the following:

Sunday, June 1, 2014, 8:00 am  –  11:45 am (poster presentation)

Title: A phase 1 study of phospholipid ether [131I]-CLR1404 in patients with advanced solid tumors (Abstract #130053; Poster #20)

Presenter: Sam J. Lubner, M.D., University of Wisconsin School of Medicine and Public Health, Madison, WI

Session: Developmental Therapeutics General Poster Session

Monday, June 2, 2014, 3:00 p.m. – 3:12 p.m. (oral presentation)

Title: A novel "diapeutic" molecular imaging agent for combined oncologic diagnosis and therapy in a broad spectrum of human cancers: Preliminary clinical experience with CLR1404 (Abstract #11000)

Presenter: Perry J. Pickhardt, M.D., University of Wisconsin School of Medicine and Public Health, Madison, WI

Session: Tumor Biology Session

All abstracts can be accessed through the ASCO website, http://abstract.asco.org/ . After the presentations and posters are public, they will be available as PDFs on Cellectar's website at www.cellectar.com .

About Cellectar Biosciences, Inc.

Cellectar Biosciences is developing agents to detect, treat and monitor a broad spectrum of cancers. Using a novel phospholipid ether analog (PLE) platform technology as a targeted delivery and retention vehicle, Cellectar's compounds are designed to be selectively taken up and retained in cancer cells including cancer stem cells. With the ability to attach both imaging and therapeutic agents to its proprietary delivery platform, Cellectar has developed a portfolio of product candidates engineered to leverage the unique characteristics of cancer cells to "find, treat and follow" malignancies in a highly selective way. I-124-CLR1404 is a small-molecule, broad-spectrum, cancer-targeted PET imaging agent currently being evaluated in a Phase II glioblastoma imaging trial. Additionally, multiple investigator-sponsored Phase I/II clinical trials are ongoing across 11 solid tumor indications. I-131-CLR1404 is a small-molecule, broad-spectrum, cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells including cancer stem cells. A Phase Ib dose-escalation trial of I-131-CLR1404 in patients with advanced solid tumors was completed in the first quarter of 2014 and results have been submitted to the American Society of Clinical Oncology (ASCO) 2014 Annual Meeting. CLR1502 is a preclinical, cancer-targeted, non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging. For additional information please visit www.cellectar.com

This news release contains forward-looking statements. You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended December 31, 2013. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.

 CONTACT: INVESTOR CONTACT                      Kate McNeil, Vice President of IR, PR & Corporate Communications           Cellectar Biosciences, Inc.           Phone: (347) 204-4226           Email: kmcneil@cellectar.com 

Cellectar Biosciences, Inc. Logo

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Align Wagner Collection Tests Men's Footwear Depth

Updated Category News Views 18

Three pairs of shoes are not a revolution, but they can expose whether a young brand has its footing. Align, established in 2025 by H.H. Brown, is rolling out the Wagner collection for Fall-Winter 2026 with a waterproof boot, a penny loafer and a lace-up oxford. That is a sensible little arsenal, not some overstuffed catalog dreamed up by a marketing committee that has...

Continue Reading
COFE+ Barista Test Puts Robotic Coffee on the Clock

Updated Category News Views 84

A swan latte taking 18 seconds less is not nothing, even if it is hardly a verdict on the future of coffee. COFE+, the seventh-generation robotic barista from Shanghai Hi-Dolphin Robot Technology, beat an award-winning human barista across five drinks at a live November 14 competition in Yiwu. That is a clean, visible demonstration of what machines are increasingly built...

Continue Reading
Pinnacol’s Community Work Earns Denver Chamber Recognition

Updated Category News Views 13

A workers’ comp insurer usually becomes visible on somebody’s worst day; Pinnacol Assurance is being recognized for the work it keeps doing around those days. The Denver Metro Chamber of Commerce has given the Colorado-based, member-owned carrier its 2026 Business Impact Award for Corporate Social Responsibility. Awards can be cheap applause, frankly. This one...

Continue Reading
Cash Flow Discipline Is Where Business Growth Gets Real

Updated Category News Views 55

A full order book can still leave a company gasping at payroll. That is the unglamorous point behind the Nov. 20, 2026, HelloNation piece featuring Kimberly Furrh of Furrh & Associates PC in Lawton, Oklahoma. Owners love to talk about sales because sales are visible, flattering and easy to celebrate. Cash is less theatrical. It is also the thing that keeps the lights on...

Continue Reading
West Virginia SEO Timelines Demand Patience, Not Hype

Updated Category News Views 68

A fresh website with no search footprint is not a race car; it is a pickup stuck in mud, and Sean O'Kelly's view of local SEO in West Virginia puts that inconvenient fact right on the table. Most businesses can expect measurable improvement after three to six months of consistent work, according to the HelloNation article. That is not a glamorous answer, but it is the...

Continue Reading
AV Access iDock B12 Chases the Growing Two-PC Desk Boom

Updated Category News Views 149

Cable spaghetti has become an oddly durable tax on anyone running a work laptop beside a gaming tower, and AV Access is taking a proper swing at it with the iDock B12. This is not some mystical new category; it is a KVM switch and docking station mashed together for a desk that has to serve two masters. Still, the company has aimed at the parts that usually get sacrificed...

Continue Reading
Classic Chevrolet Gives $1.145M to 13 Local Groups

Updated Category News Views 26

A Thanksgiving Check With Some Real Weight More than a million dollars changing hands before lunch is not the usual holiday fluff, and Classic Chevrolet's planned $1,145,040 donation deserves more than a quick nod. On Tuesday, November 24, at 11 a.m. CST, the Grapevine dealership says it will distribute that sum among 13 nonprofit organizations and charitable programs...

Continue Reading
Nevada’s Space Academy Bid Has Assets, Not a Win Yet

Updated Category News Views 29

Desert acreage and a moon-landing backstory make for a handsome pitch, but Nevada is still standing at the starting line. The state has submitted its official response to NASA’s Request for Information for a proposed United States Space Academy, and the new promotional video is meant to show why the Silver State belongs in the conversation. Fair enough. There is real...

Continue Reading
Huawei's Financial AI Push Targets Scale, Not Demos

Updated Category News Views 79

Banking AI has reached the point where a clever chatbot barely moves the needle. Huawei's message at Singapore FinTech Festival 2026 was aimed squarely at that harder, more expensive problem: turning AI from a scattered pilot project into machinery a financial institution can operate, govern, repeat, and improve without handing over its crown jewels. Ownership Is the...

Continue Reading
Payoneer Gets OCC Nod, but the Finish Line Is Ahead

Updated Category News Views 78

Federal bank paperwork is not usually thrilling, yet Payoneer just found a potentially meaningful lever for its cross-border payments machine. The company received preliminary conditional approval from the Office of the Comptroller of the Currency to form PAYO Digital Bank, a national trust bank intended to support stablecoin services. That is a real regulatory milestone...

Continue Reading

Top 5 Most Recently Viewed Articles

CMG Teams Up with NVIDIA for Enhanced Simulation Technology

Updated Category News Views 70

Innovative Partnership for Advanced Simulation Solutions Computer Modelling Group Ltd. (CMG) is embarking on a transformative journey by collaborating with NVIDIA, aiming to revolutionize their subsurface simulation solutions. This partnership is set to enhance speed, performance, and energy efficiency, showcasing CMG's commitment to staying at the forefront of...

Continue Reading
Understanding P/E Ratios: A Deep Dive into Zimmer Biomet Holdings

Updated Category News Views 224

Understanding P/E Ratios and Their Importance The price-to-earnings (P/E) ratio is a vital metric in assessing a company's valuation. Current trading for Zimmer Biomet Holdings Inc. (ZBH) shares has reached $97.99, reflecting a noteworthy increase of 1.52%. Over the past month, this stock has climbed by 5.16%, contrasting a year-over-year decline of 12.03%. Investors are...

Continue Reading
Breakthrough Outcomes of Telitacicept in Sjögren's Syndrome Study

Updated Category News Views 220

Exciting Developments in Telitacicept Phase III Trial Results The Phase III clinical trial results for Telitacicept are sparking significant interest, particularly within the realm of Sjögren's Syndrome. This autoimmune condition can severely affect patients' quality of life due to symptoms like dry mouth and dry eyes, among others. Recently, announcements surrounding...

Continue Reading
BioCryst Pharmaceuticals Shares Mixed Q4 Earnings and Trial Insights

Updated Category News Views 234

Promising Results from BioCryst Pharmaceuticals' APeX-P Trial BioCryst Pharmaceuticals, Inc. has recently revealed noteworthy findings from the interim analysis of its APeX-P trial. This ongoing study focuses on an innovative oral granule formulation of Orladeyo (berotralstat) designed for once-daily use in pediatric patients suffering from hereditary angioedema (HAE)....

Continue Reading
Supermicro Reveals Advanced Server Design for Edge AI Solutions

Updated Category News Views 109

Supermicro Unveils New Infrastructure for AI Efficiency Super Micro Computer, Inc. (SMCI) has recently launched an innovative 3U server designed to support up to 18 GPUs while integrating dual Intel® Xeon® 6900 series processors equipped with P-cores. This powerful system is strategically engineered for artificial intelligence inferencing at the edge, meeting the...

Continue Reading